目的 探討止喘靈口服液聯(lián)合特布他林治療兒童支氣管哮喘的臨床療效。方法 選取2021年10月—2022年10月黃河三門峽醫(yī)院收治的110例支氣管哮喘患兒，以隨機(jī)數(shù)字表分為對(duì)照組和治療組，每組55例。對(duì)照組霧化吸入硫酸特布他林霧化吸入用溶液治療，體質(zhì)量≥20 kg的患兒以5 mg藥液霧化吸入，3次/d；體質(zhì)量＜20 kg的患兒以2.5 mg藥液霧化吸入，4次/d。治療組在對(duì)照組治療基礎(chǔ)上增加止喘靈口服液治療，硫酸特布他林霧化吸入用溶液用藥方案與對(duì)照組相同，止喘靈口服液10 mL/次，3次/d。兩組均以7 d為1療程，治療1個(gè)療程。觀察兩組臨床療效，比較治療前后兩組肺功能指標(biāo)、相關(guān)量表評(píng)分、氣道炎癥指標(biāo)和血清炎癥因子水平。結(jié)果 治療后，治療組總有效率是92.73%，顯著高于對(duì)照組的80.00%（P＜0.05）。治療后，兩組最大呼氣第1秒容積（FEV1）、用力肺活量（FVC）、最大呼氣峰流速（PEF）、最大呼氣第1秒容積/用力肺活量（FEV1/FVC）均顯著提高（P＜0.05）；治療后，治療組FEV1、FVC、PEF、FV1/FVC高于對(duì)照組（P＜0.05）。治療后，兩組兒童哮喘控制測(cè)試評(píng)分（C-ACT）、兒科哮喘生活質(zhì)量調(diào)查問(wèn)卷（PAQLQ）評(píng)分均升高（P＜0.05）；治療后治療組C-ACT、PAQLQ高于對(duì)照組（P＜0.05）。治療后，兩組痰中嗜酸性粒細(xì)胞（EOS）比例、呼出氣一氧化氮（FeNO）水平均顯著降低（P＜0.05）；治療后，治療組患者痰中EOS比例、呼出氣FeNO水平低于對(duì)照組（P＜0.05）。治療后，兩組白細(xì)胞介素-8（IL-8）、白細(xì)胞介素-17（IL-17）、C反應(yīng)蛋白（CRP）水平均顯著降低（P＜0.05）；治療后，治療組IL-8、IL-17、CRP水平均低于對(duì)照組（P＜0.05）。結(jié)論 止喘靈口服液聯(lián)合特布他林治療兒童支氣管哮喘效果良好，能提升肺功能指標(biāo)，降低患兒的氣道炎癥指標(biāo)和血清炎癥因子水平，改善患兒生活質(zhì)量。

Objective To study the clinical efficacy of Zhichuanling Oral Liquid combined with terbutaline in treatment of bronchial asthma in children. Methods A total of 110 children with bronchial asthma admitted to Yellow River Sanmenxia Hospital from October 2021 to October 2022 were selected and divided into control group and treatment group by random number table, with 55 cases in each group. Children in control group were nebulized inhalation of Terbutaline Sulfate Nebuliser Solution, for children with body weight of ≥ 20 kg, 5 mg of the drug solution is nebulized and inhaled three times daily. For children with body weight of < 20 kg, 2.5 mg of the drug solution should be nebulized and inhaled 4 times daily. Children in treatment group were treated with Zhichuanling Oral Liquid on the basis of control group’s treatment. The medication regimen for terbutaline sulfate nebulized inhalation solution was the same as that of control group. The dosage of Zhichuanling Oral Liquid was 10 mL each time, three times daily. Both groups were treated for 7 d as one course of treatment, with one course of treatment. The clinical efficacy of two groups was observed, and the pulmonary function indicators, related scale scores, airway inflammation indicators and serum inflammatory factor levels of two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 92.73%, significantly higher than that of control group (80.00%, P < 0.05). After treatment, FEV1, FVC, PEF, and FEV1/FVC in both groups were significantly increased (P < 0.05). After treatment, the levels of FEV1, FVC, PEF, and FV1/FVC in treatment group were higher than those in control group (P < 0.05). After treatment, the scores of C-ACT and PAQLQ in both groups increased (P < 0.05). After treatment, the C-ACT and PAQLQ in treatment group were higher than those in control group (P < 0.05). After treatment, the proportion of EOS in sputum and the level of FeNO in both groups were significantly decreased (P < 0.05). After treatment, the proportion of EOS in sputum and the FeNO level in exhaled breath of patients in treatment group were lower than those in control group (P < 0.05). After treatment, the levels of IL-8, IL-17, and CRP in both groups were significantly decreased (P < 0.05). After treatment, the levels of IL-8, IL-17, and CRP in treatment group were all lower than those in control group (P < 0.05). Conclusion Zhichuanling Oral Liquid combined with terbutaline is clinically significant in treatment of bronchial asthma in children, can improve the lung function of children, reduce airway inflammation indicators and serum inflammatory factor levels, which can improve life quality of children.

R974;R985

河南省醫(yī)學(xué)科技攻關(guān)聯(lián)合共建項(xiàng)目（20221041）